Company intelligence
Elephas
Live tumor profiling for immunotherapy response prediction
Biotechnology Research
Madison, US
157 employees
Founded 2020
3 public signals
About Elephas
Elephas has developed an ex-vivo platform to assess how live patient biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the elive™ platform enables a real-time characterization of immune response. To learn more, visit www.elephas.com
Verified activity
Signals from Elephas
3 published signals
Research & Knowledge
Elephas introduced an AI Avatar that quickly walks through the ASCO2026 poster showing 93% concordance between a cancer patient's clinical response on immunotherapy and the Functional Precision Medicine platform's predicted response.
Reported by Hinco J. Gierman, PhD
Products & Services
Elephas launched elive, a platform designed to assess real immune behavior in live tumor biopsies beyond current predictive biomarkers.
Reported by Elephas
Research & Knowledge
Elephas presented new data on the elive™ index, a classifier of ex vivo immune checkpoint inhibitor (ICI) response built from live tumor fragments at ASCO26.
Reported by Elephas